"Breast cancer"

It is estimated that ninety percent of deaths from breast cancer are caused by complications from metastasis, so how to effectively stop breast cancer metastasis has long been a hot topic in cancer research.

With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.

St. Marianna's Medical University Hospital is one of the top hospitals in Japan, specializing in breast surgery and other related diseases.

DZD1516 is a reversible, selective HER2-targeting agent with full blood-brain barrier penetration. It has demonstrated good therapeutic response in phase I studies in patients with metastatic HER2-positive breast cancer, including breast cancer patients with central nervous system metastases.

The FDA granted priority review status to Enhertu (DS-8201) for the treatment of patients with HR-positive, low HER2-expressing breast cancer, and Enhertu has enabled these patients to remain disease-free for an average of 10.1 months, with an average overall survival time of nearly two years. A decision on approval is expected to be made in the fourth quarter of this year.